|
gptkbp:instanceOf
|
gptkb:chemical_compound
local anesthetic
stimulant
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:ATCCode
|
N01BA01
|
|
gptkbp:CASNumber
|
53-21-4
|
|
gptkbp:chemicalFormula
|
C17H21NO4·HCl
|
|
gptkbp:color
|
white
|
|
gptkbp:controlledBy
|
gptkb:DEA
gptkb:FDA
|
|
gptkbp:discoveredBy
|
gptkb:Albert_Niemann
|
|
gptkbp:discoveredIn
|
1860
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:flavor
|
bitter
|
|
gptkbp:halfLife
|
0.7–1.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cocaine hydrochloride
|
|
gptkbp:IUPACName
|
gptkb:methyl_(1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate_hydrochloride
|
|
gptkbp:legalStatus
|
Class A drug (UK)
Schedule II controlled substance (US)
|
|
gptkbp:meltingPoint
|
197°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
339.8 g/mol
|
|
gptkbp:origin
|
derived from coca plant (Erythroxylum coca)
|
|
gptkbp:parent_compound
|
cocaine
|
|
gptkbp:produces_effect
|
vasoconstriction
numbing
stimulation
|
|
gptkbp:PubChem_CID
|
gptkb:DB00907
CHEMBL504
5761
|
|
gptkbp:riskFactor
|
addiction
neurotoxicity
cardiotoxicity
high abuse potential
|
|
gptkbp:routeOfAdministration
|
oral
topical
intranasal
|
|
gptkbp:sideEffect
|
addiction
anxiety
hypertension
tachycardia
euphoria
|
|
gptkbp:solubility
|
water-soluble
|
|
gptkbp:UNII
|
I5Y540LHVR
|
|
gptkbp:used_in
|
dental procedures
nasal surgery
ophthalmic procedures
|
|
gptkbp:usedFor
|
local anesthesia of mucous membranes
topical anesthetic
|
|
gptkbp:bfsParent
|
gptkb:Base_(drug_culture)
|
|
gptkbp:bfsLayer
|
5
|